However, very little data are available in the literature on the use of Midazolam to treat acute agitation in elderly demented patients.
The tolerability of Midazolam is well described in the emergency management of agitation in young patients, when administered intramuscularly, intravenously or by intranasal route, but no data are currently available for other routes of administration or for this indication in the elderly population.
Finally, recommendations are non-existent as no molecule has a specific indication in this elderly population.
The purpose of this literature review therefore was to identify studies where tolerability of Midazolam was reported, with a specific analysis of studies reporting tolerability of oral administration of Midazolam and those in elderly population. We hope that obtaining an improved understanding of these factors could assist in confirming the interest of oral Midazolam in this population to make detailed recommendations and optimize the care of elderly demented patients with uncontrolled behavioural disorders.
| ME THODS
This systematic review was conducted according to PRISMA guidelines. We performed, the 18th of December 2017, an advanced com- Analysis was limited to descriptive statistics.
| RE SULTS AND D ISCUSS I ON
The search strategy generated 2278 citations: 2129 from database searches and 67 from manual research on reference list. Two thousand and thirty citations were excluded as irrelevant after checking their titles and abstracts. We identified 99 full-text articles from which 58 did not meet the inclusion criteria. Forty-one studies specifically presented numerical data on tolerability of Midazolam in the adult population, whatever the age, the route and the indication were included. The flow chart of the studies involved in the systematic review is shown in Figure 1 .
The 41 articles included were published between 1983 and 2017. Twenty four studies (58.5%) were randomized controlled trials, 15 were cohort studies (36.6%), and two studies (4.9%) were clinical case studies.
The number of subjects participating in these studies was between 1 and 3031 for a total of 6165 subjects. The mean age was 56.2 ± 8.8 years. Nearly fifty per cent of studies (n = 19) included a population of subjects with a mean age equal or over 60 years (the mean age of this group was 73.5 ± 7.8 years). The indication for the use of Midazolam was as follow: in 17 studies (41.5%) for a pre-endoscopic procedure, in 12 studies (29.3%) to treat agitation for psychiatric patients in emergency departments, in five studies (12.2%) for F I G U R E 1 Flow diagram of the studies screened, assessed for eligibility and included in the systematic review surgical procedures, in four studies (9.8%) for procedural sedation in emergency departments and in three studies (7.3%) for other indications including dental procedures.
The dose of Midazolam used was very variable-from 0.02 to 15 mg/kg. The route used was intravenous in 63.4%, oral in 36.4% and intramuscular in 19.5%. In one study, the route was subcutaneous and in one study nasal. In 11 studies, Midazolam was given in addition to another drug (Fentanyl, Propofol, Meperidine, Pethidine, Piritramide or Droperidol). Eleven different adverse events were isolated from the studies with various total proportions. They concerned cardiac and pulmonary complication, hypotension, tachycardia, bradycardia, desaturation below 90%, airway obstruction, pulmonary infection, excessive sedation, hyperactivity, delirium and vomiting. These results are summarized on Table 1 We performed a subgroup analysis for the two main adverse events reported, (hypotension and desaturation below 90%) according to the mean age of the population (>60 years or ≤60 years), the route used (Oral vs other route), the indication (To treat agitation vs to achieve sedation) and whether the Midazolam was used in association with other drugs or not. The results are presented in Table 2 .
No significant difference was found for hypotension whatever the route or the indication. Desaturation below 90% was significantly more frequent in the group with a mean age >60 years, when achieving sedation, when Midazolam was not used orally or was used in association with other drugs.
Midazolam seems to be a suitable pharmacological agent for the treatment of agitation in this population, considering that the preferred drugs are those with short-term effectiveness that contribute to tranquilization but do not delay recovery; all the more so as an effective antidote exists. 45 The two main adverse reactions reported in our review appear to be more common in the populations of patients with mean age over 60 years but also in the situations where Midazolam was used in combination with other drugs. However, rates of these adverse effects remain lower than those described with neuroleptic drugs whose adverse effects rates are age-dependent and not dose-dependent. 46 In our study, the oral route appears to be the most appropriate to provide a rapid and well-tolerated response even more so other routes that can be used for Midazolam may present many disagreements.
The subcutaneous route of administration is the simplest, but an erratic absorption can be seen in the elderly population especially in the case of sarcopenia 47 which leads to great intra-individual variability and poor predictability of the response of Midazolam. 48 For the intravenous route of administration, the venous condition of the patient must be good, which is often not the case in the elderly population and requires aggressive restraint. 10 Lastly; intramuscular administration remains very controversial 47 because it presents many disadvantages: the injection can be painful and is contraindicated in case of anticoagulant treatment while having a longer delay of action (15-25 minutes) and does not avoid the use of restraint.
| WHAT IS NE W AND CON CLUS I ON
The aim of our study was to access tolerability of oral Midazolam to treat acute agitation in elderly demented patients as few data exist concerning this route and indication.
Indeed, the oral route of administration of Midazolam seems to be useful as well tolerated and can be an effective alternative in this indication. We acknowledge that conclusions of our study are limited by the methodology used. It however highlights the significant potential of this therapy, but as long as it is recommended for shortterm use such as treatment of acute agitation, given the danger of extended exposure and/or of co-administration with opioid and neuroleptic medications that multiplies the risk of life-threatening overdoses and death by central nervous system depression. 49 New research is required in order to provide further information in terms of pharmacodynamics and delay of action of oral Midazolam in the elderly population. These results will also give appropriate
TA B L E 1 Main characteristics of the included studies

Studies (n) 41
Total number of subjects participating in the studies (n) In conclusion, further surveys will be needed to better understand the balance of risks and benefits of these various routes of administration and to confirm the usefulness and the good tolerance of oral Midazolam in the management of acute agitation in elderly demented patients.
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